NCT05479240View on ClinicalTrials.gov

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2028

Conditions
Immunotherapy
Interventions
DRUG

Tislelizumab

Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 cycles.

DRUG

Capecitabine

Participants will receive Capecitabine, 1000mg/m2, day 1-14 of every 3 weeks for 6 cycles

DRUG

oxaliplatin

Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 6 cycles.

RADIATION

short-range radiotherapy

5\*5Gy，d1-d5

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV